Molecular based subtyping of feline mammary carcinomas and clinicopathological characterization

Breast

Volumn 27, Issue , 2016, Pages 44-51

  Soares, Maria ^a   Madeira, Sara ^a   Correia, Jorge ^a   Peleteiro, Maria ^a   Cardoso, Fátima ^b   Ferreira, Fernando ^a  

^a FACULDADE DE MEDICINA VETERINÁRIA   (Portugal)

^b CHAMPALIMAUD CLINICAL CENTER   (Portugal)

Author keywords

Cancer model; Feline mammary carcinoma; Immunohistochemistry; Luminal B; Molecular subtype; Triple negative

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; BREAST LESION; BREAST NECROSIS; CANCER CLASSIFICATION; CANCER SIZE; CANCER SURVIVAL; CAT DISEASE; CLINICAL FEATURE; CONSENSUS; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOLECULAR DIAGNOSIS; MOLECULAR GENETICS; NONHUMAN; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; CAT; CHEMISTRY; CLASSIFICATION; EXPERIMENTAL MAMMARY NEOPLASM; SURVIVAL ANALYSIS;

ANIMALS; CAT DISEASES; CATS; FEMALE; MAMMARY NEOPLASMS, ANIMAL; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS;

EID: 84961207018     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2016.02.016     Document Type: Article

References (54)

1. Sorenmo K.U., Worley D.R., Goldschmidt M.H. Tumors of the mammary gland. Small animal clinical oncology. Withrow SJ, Vail DM & Page RL 2013, 538-556. Saunders Elsevier, Missouri, US. 5th ed.
2. De Maria R., Olivero M., Iussich S., Nakaichi M., Murata T., Biolatti B., et al. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Res 2005, 65(3):907-912.
3. de las Mulas J.M., Reymundo C. Animals models of human breast carcinoma: canine and feline neoplasms. Rev Oncol 2000, 2:274-281.
4. Szabo S., Haislip A.M., Garry R.F. Of mice, cats, and men: is human breast cancer a zoonosis?. Microsc Res Tech 2005, 68(3-4):197-208.
5. Salmons B., Gunzburg W.H. Revisiting a role for a mammary tumor retrovirus in human breast cancer. Int J Cancer 2013, 133:1530-1536.
6. Herbein G., Kumar A. The oncogenic potential of human cytomegalovirus and breast cancer. Front Oncol 2014, 4:230.
7. Wildschutte J.H., Ram D., Subramanian R., Stevens V.L., Coffin J.M. The distribution of insertionally polymorphic endogenous retroviruses in breast cancer patients and cancer-free controls. Retrovirology 2014, 11:62.
8. Ohba K., Ichiyama K., Yajima M., Gemma N., Nikaido M., Wu Q., et al. In vivo and in vitro studies suggest a possible involvement of HPV infection in the early stage of breast carcinogenesis via APOBEC3B induction. PLoS One 2014, 9(5). e97787.
9. Szabo S., Haislip A.M., Traina-Dorge V., Costin J.M., Crawford B.E., Wilson R.B., et al. Human, rhesus macaque, and feline sequences highly similar to mouse mammary tumor virus sequences. Microsc Res Tech 2005, 68:209-221.
10. Edwards B.K., Noone A.M., Mariotto A.B., Simard E.P., Boscoe F.P., Henley S.J., et al. Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast or prostate cancer. Cancer 2014, 120(9):1290-1314.
11. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
12. Park S., Koo J.S., Kim M.S., Park H.S., Lee J.S., Lee J.S., et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by panel of four biomarkers using immunohistochemistry. Breast 2012, 21:50-57.
13. Ribelles N., Perez-Villa L., Jerez J.M., Pajares B., Vicioso L., Jimenez B., et al. Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. Breast Cancer Res 2013, 15. R98.
14. Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., Piccart-Gebhart M., Thürlimann B., et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol 2013, 24(9):2206-2223.
15. Eroles P., Bosch A., Pérez-Fidalgo J.A., Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev 2012, 38:698-707.
16. Cheang M.C., Chia S.K., Voduc D., Gao D., Leung S., Snider J., et al. Ki67 index, HER2 status, and prognosis of patients with Luminal B breast cancer. J Natl Cancer Inst 2009, 101:736-750.
17. Reis-Filho J.S., Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011, 378:1812-1823.
18. Curigliano G. New drugs for breast cancer subtypes: targeting driver pathways to overcome resistance. Cancer Treat Rev 2012, 38:303-310.
19. Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 2001, 98(19):10869-10874.
20. Gusterson B., Ross D.T., Heath V.J., Stein T. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 2005, 7:143-148.
21. Eerola H., Heinonen M., Heikkilä P., Kilpivaara O., Tamminen A., Aittomäki K., et al. Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 2008, 10:1.
22. Bosch A., Eroles P., Zaragoza R., Viña J.R., Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 2010, 36:206-215.
23. Millanta F., Lazzeri G., Mazzei M., Vannozzi Poli A. MIB-1 labeling index in feline dysplastic and neoplastic mammary lesions and its relationship with postsurgical prognosis. Vet Pathol 2002, 39:120.
24. Sarli G., Preziosi R., Benazzi C., Bazzo R., Mandrioli L., Marcato P.S. Rate of apoptosis in feline mammary tumors is not predictive of postsurgical survival. J Vet Diagn Invest 2003, 15:115-122.
25. Millanta F., Calandrella M., Citi S., Della Santa D., Poli A. Overexpression of HER-2 in feline invasive mammary carcinomas: na immunohistochemical survey and evaluation of its prognostic potential. Vet Pathol 2005, 42:30-34.
26. Millanta F., Calandrella M., Vannozzi I., Poli A. Steroid hormone receptors in normal, dysplastic and neoplastic feline mammary tissues and their prognostic significance. Vet Rec 2006, 158(24):821-824.
27. Millanta F., Citi S., Della Santa D., Porciani M., Poli A. COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic molecular markers. Breast Cancer Res Treat 2006, 98:115-120.
28. Burrai G.P., Mohammed S.I., Miller M.A., Marras V., Pirino S., Addis M.F., et al. Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions. BMC Cancer 2010, 10:156.
29. Seixas F., Palmeira C., Pires M.A., Bento M.J., Lopes C. Grade is an independent prognostic factor for feline mammary carcinoma: a clinicopathological and survival analysis. Vet J 2011, 187(1):65-71.
30. Islam M.S., Matsumoto M., Hidaka R., Miyoshi N., Yasuda N. Expression of NOS and VEGF in feline mammary tumours and their correlation with angiogenesis. Veterinary J 2012, 192:338-344.
31. Peñafiel-Verdu C., Buendia A.J., Navarro J.A., Ramirez G.A., Vilafranca M., ALtimira J., et al. Reduced expression of E-cadherin and β-catenin and high expression of basal cytokeratins in feline mammary carcinomas with regional metastasis. Veterinary Pathol 2012, 49(6):979-987.
32. Soares M., Ribeiro R., Carvalho S., Peleteiro M., Correia J., Ferreira F. Ki-67 as a prognostic factor in feline mammary carcinoma: what is the optimal cutoff value?. Vet Pathol 2016, 53(1):37-43.
33. Weijer K., Hart A.A.M. Prognostic factors in feline mammary carcinoma. J Natl Cancer Inst 1983, 70(4):709-716.
34. MacEwen E.G., Hayes A.A., Harvey H.J., Patnaik A.K., Mooney S., Passe S. Prognostic factors for feline mammary tumors. J Am Vet Med Assoc 1984, 185(2):201-204.
35. Brunetti B., Asproni P., Beha G., Muscatello L.V., Millanta F., Poli A., Benazzi C., et al. Molecular phenotype in mammary tumours of queens: correlation between primary tumour and lymph node metastasis. J Comp Pathol 2013, 148(2-3):206-213.
36. Soares M., Correia J., Murta A., Ferreira F. Immunophenotyping of primary and metastatic lesions in feline mammary tumors - are they equal?. Microsc Microanal 2013, 19(Suppl. 4):19-20.
37. Wiese D.A., Thaiwong T., Yuzbasiyan-Gurkan V., Kiupel Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype. BMC Cancer 2013, 13:403.
38. Misdorp W., Else R.W., Hellmen E., Lipscomb T.P. Histologic classification of mammary tumors of the dog and the cat. World Health Organization international histological classification of tumours of domestic animals 1999, vol. 7:11-27. Armed Force Institute of Pathology and World Health Organization, Washington, DC. 2th ed.
39. Elston C.W., Ellis I.O. Assessment of histological grade. Rosen's breast pathology 1998, 365-382. Lippincott-Raven, Philadelphia. P.P. Rosen (Ed.).
40. Soares M., Correia J., Rodrigues P., Simões M., de Matos A., Ferreira F. Feline HER2 protein expression levels and gene status in feline mammary carcinoma: optimization of immunohistochemistry (IHC) and In Situ Hybridization (ISH) techniques. Microsc Microanal 2013, 19:1-7.
41. Soares M., Correia J., Peleteiro M.C., Ferreira F. St Gallen molecular subtypes in feline mammary carcinoma and paired metastases - disease progression and clinical implications from a 3-year follow-up study. Tumor Biol 2015, 10.1007/s13277-015-4251-z.
42. Wolff A.C., Hammond M.E., Hicks D.G., Dowsett M., McShane L.M., Allison K.H., et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice guideline update. J Clin Oncol 2013, 31(31):3997-4014.
43. Hammond M.E., Hayes D.F., Dowsett M., Allred D.C., Hagerty K.L., Badve S., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010, 134(7):48-72.
44. Harvey J.M., Clark G.M., Osborne C.K., Allred C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17(5):1474-1481.
45. Adamczyk A., Niemiec J., Ambicka A., Malecki K., Wysocki W.H., Mitus J., et al. Expression of ER/PR/HER2, basal markers and adhesion molecules in primary breast cancer and in lymph nodes metastases: a comparative immunohistochemical analysis. Pol J Pathol 2012, 63:226-234.
46. Ferguson N.L., Bell J., Heidel R., Lee S., Vanmeter S., Duncan L., et al. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, and pathologic tumor characteristics on breast cancer survival in caucasian women. Breast J 2013, 19(1):22-30.
47. Caldarella A., Buzzoni C., Crocetti E., Bianchi S., Vezzosi V., Apicella P., et al. Invasive breast cancer: a significant correlation between histological types and molecular subgroups. J Cancer Res Clin Oncol 2013, 139:617-623.
48. Vallejos C.S., Gómez H.L., Cruz W.R., Pinto J.A., Dyer R.R., Velarde R., et al. Breast Cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a Peruvian Hospital database. Clin Breast Cancer 2010, 10(4):294-300.
49. Gama A., Alves A., Schmitt F. Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. Virchows Arch 2008, 453:123-132.
50. Lam S.W., Jimenez C.R., Boven E. Breast cancer classification by proteomic technologies: current state of knowledge. Cancer Treat Rev 2014, 40:129-138.
51. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
52. Livasy C.A., Karaca G., Nanda R., Tretiakova M.S., Olopade O.I., Moore D.T., et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006, 19:264-271.
53. Sassi F., Benazzi C., Castellani G., Sarli G. Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry. BMC Veterinary Res 2010, 6:5.
54. Saad R.S., Denning K.L., Finkelstein S.D., Liu Y., Pereira T.C., Lin X., et al. Diagnostic and prognostic utility of molecular markers in synchronous bilateral breast carcinoma. Mod Pathol 2008, 21:1200-1207.